Malignant Pleural Effusion Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Projected Growth of the Malignant Pleural Effusion Market?
In recent years, there has been robust growth in the size of the malignant pleural effusion market. The market will expand from a value of $4.42 billion in 2024 to $4.74 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.1%. The upward trajectory during the historical timeframe can be linked to factors such as the wider adoption of indwelling pleural catheters, an amplified focus on palliative care, an increase in clinical trials, growing acknowledgment from insurance companies, and an upsurge in metastatic malignancies.

The market size for malignant pleural effusion is forecasted to experience substantial growth over the next several years, soaring to $6.17 billion by 2029 with a CAGR of 6.8%. The predicted growth during this forecast period can be linked to improvements in healTH*Care infrastructure, increased government backing, a rise in the number of cancer survivors, a growing demand for care at home, and the expanding liquid biopsy market. Key trends expected during this period consist of incorporating artificial intelligence into imaging tools, the development of targeted cancer therapies, advancements in pleurodesis, the refinement of biomarkers, and the growth of clinical trials exploring new therapeutic agents.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22047

What Are the Different Malignant Pleural Effusion Market Segments?
The malignant pleural effusion market covered in this report is segmented -

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter
2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy
3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegmentss:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis
3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis, Mechanical Pleurodesis, Biological Pleurodesis
4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

What Are the Primary Drivers Shaping the Malignant Pleural Effusion Market?
The escalating prevalence of lung cancer is anticipated to boost the malignant pleural effusion market's expansion in the foreseeable future. Lung cancer is identified by unrestrained growth of abnormal cells in the lungs. These abnormal cells can form tumors and disrupt regular lung function. The increasing instances of lung cancer result primarily from smoking and tobacco consumption, as continuous exposure to hazardous substances in cigarettes can damage lung tissues, initiate genetic mutations, and foster uncontrolled growth of cancer cells, dramatically escalating the risk of disease development. Malignant pleural effusion typically signifies the progression of lung cancer to an advanced stage, promoting tumor spread within the pleural cavity, diminishing respiratory functionality, and predicting a poorer prognosis. For example, as per the American Cancer Society Facts and Figures in January 2023, there were approximately 236,740 and 238,340 new cases of lung and bronchus cancer in 2022 and 2023, respectively, while the estimated death count was 130,180 in 2022 and 127,070 in 2023. Therefore, the swelling number of lung cancer cases is fueling the malignant pleural effusion market's growth. The improvement in healTH*Care infrastructure is foreseen as a significant force propelling the malignant pleural effusion market's expansion. The term 'healTH*Care infrastructure' embodies the physical, technological, and organizational structures necessary for healTH*Care service delivery, inclusive of hospitals, clinics, medical equipment, IT systems, and workforce. Enhanced healTH*Care accessibility, efficiency, and quality of care result from upgrading healTH*Care infrastructure for improved disease management. Enhanced healTH*Care infrastructure better diagnoses, treats, and manages malignant pleural effusion by providing access to cutting-edge medical technologies, higher-quality healTH*Care facilities, and specialized care, significantly enhancing patient outcomes. For example, according to The American Health Care Association in May 2023, the count of hospitals in the United States rose by 0.591% from the preceding year, escalating from 6,093 to 6,129. Consequently, the improvement in healTH*Care infrastructure is fueling the growth of the malignant pleural effusion market.

Which Companies Are Leading in the Malignant Pleural Effusion Market?
Major companies operating in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH

What Are the Major Trends Shaping the Malignant Pleural Effusion Market?
Key players in the malignant pleural effusion market are centring their efforts on creating novel therapies, such as enzyme-targeting therapy, for enhancing treatment effectiveness by targeting particular enzymes involved in fluid accumulation. Enzyme-targeting therapy is a medical method which involves the crafting of drugs or treatments that specifically disrupt or change the functioning of disease-associated enzymes. It is frequently employed in cases such as cancer, metabolic diseases, and infectious diseases, where abnormal enzyme activity accelerates the development of the disease. For instance, in September 2022, a clinical trial called MITOPE was initiated by RS Oncology, LLC, a US-based biotech firm. This UK-based Phase 1/2 trial is evaluating RSO-021, a unique PRX3 inhibitor, which is designed to treat malignant pleural effusion and mesothelioma by targeting oxidative stress, thereby eliminating cancer cells while sparing healthy tissue.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

What Are the Top Revenue-Generating Geographies in the Malignant Pleural Effusion Market?
North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Malignant Pleural Effusion Market?
2. What is the CAGR expected in the Malignant Pleural Effusion Market?
3. What Are the Key Innovations Transforming the Malignant Pleural Effusion Industry?
4. Which Region Is Leading the Malignant Pleural Effusion Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.